| Thomas Darwin Persons Jr, RPH | |
|
1830 Burr Oak Ln, Adkins, TX 78101-2606 | |
| (830) 216-7998 | |
| Not Available |
| Full Name | Thomas Darwin Persons Jr |
|---|---|
| Gender | Male |
| Speciality | Pharmacist |
| Location | 1830 Burr Oak Ln, Adkins, Texas |
| Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1023302890 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 183500000X | Pharmacist | 25775 (Texas) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Thomas Darwin Persons Jr, RPH 1830 Burr Oak Ln, Adkins, TX 78101-2606 Ph: (830) 216-7998 | Thomas Darwin Persons Jr, RPH 1830 Burr Oak Ln, Adkins, TX 78101-2606 Ph: (830) 216-7998 |
News Archive
Our cells live ever on the verge of suicide, requiring the close attention of a team of molecules to prevent the cells from pulling the trigger. This self-destructive tendency can be a very good thing, as when dangerous precancerous cells are permitted to kill themselves, but it can also go horribly wrong, destroying brain cells that store memories, for instance. Rockefeller University scientists are parsing this perilous arrangement in ever finer detail in hopes that understanding the basic mechanisms of programmed cell death, or apoptosis, will enable them eventually to manipulate the process to kill the cells we want to kill and protect the ones we don't.
NeuroVive Pharmaceutical and Hospices Civils de Lyon today announced the enrollment and treatment of the first patient in the European multicenter trial of myocardial infarction.
A handful of high-profile Republicans who may be eyeing the White House told hundreds of conservative activists Saturday that most Americans agree with their values, and insisted that opposition to the president's health care overhaul could help the GOP make historic gains in 2012.
A study recently published in the journal Matter has demonstrated the development and validation of a nanoparticle-based formulation, capable of completely inhibiting the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection blocking the interaction between viral spike protein and host cell angiotensin-converting enzyme 2 (ACE2).
› Verified 6 days ago